Literature DB >> 19164923

Antiprion drugs as chemical tools to uncover mechanisms of prion propagation.

Déborah Tribouillard1, Fabienne Gug, Hervé Galons, Stéphane Bach, Sven J Saupe, Marc Blondel.   

Abstract

A number of drugs active against prions either in vitro, in cellular systems or in vivo in animal models have been isolated in various screening assays. In this minireview, we would like to suggest, that in addition to their direct interest as potential therapeutic agents, these molecules could be used as original research tools to understand prion propagation. The use of antiprion compounds as tool to understand fundamentals of prion propagation relies on reverse screening approaches. These global genetic and/or biochemical approaches aim to identify the intracellular target(s) and mechanism of action of the drugs. Once those are known, the biological activity of the compounds can be optimized on a rational basis, their potential side effects understood and minimized. In vitro enzyme-based screening assays can then be designed to allow discovery of new, more potent and selective molecules. Here we describe the main comprehensive biochemical and genetical approaches to realize reverse screening approaches based on antiprion drugs. We will finish by discussing the interest of using drug inactivation of specific targets as a substitute to genetic inactivation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19164923      PMCID: PMC2633708          DOI: 10.4161/pri.1.1.4053

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  37 in total

1.  Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation.

Authors:  K Doh-Ura; T Iwaki; B Caughey
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Using budding yeast to screen for anti-prion drugs.

Authors:  Déborah Tribouillard; Stéphane Bach; Fabienne Gug; Nathalie Desban; Vincent Beringue; Thibault Andrieu; Dominique Dormont; Hervé Galons; Hubert Laude; Didier Vilette; Marc Blondel
Journal:  Biotechnol J       Date:  2006-01       Impact factor: 4.677

3.  Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors.

Authors:  M Knockaert; N Gray; E Damiens; Y T Chang; P Grellier; K Grant; D Fergusson; J Mottram; M Soete; J F Dubremetz; K Le Roch; C Doerig; P Schultz; L Meijer
Journal:  Chem Biol       Date:  2000-06

4.  Mechanism of prion loss after Hsp104 inactivation in yeast.

Authors:  R D Wegrzyn; K Bapat; G P Newnam; A D Zink; Y O Chernoff
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

5.  A genome-wide overexpression screen in yeast for small-molecule target identification.

Authors:  Hendrik Luesch; Tom Y H Wu; Pingda Ren; Nathanael S Gray; Peter G Schultz; Frantisek Supek
Journal:  Chem Biol       Date:  2005-01

6.  Roscovitine targets, protein kinases and pyridoxal kinase.

Authors:  Stéphane Bach; Marie Knockaert; Jens Reinhardt; Olivier Lozach; Sophie Schmitt; Blandine Baratte; Marcel Koken; Stephen P Coburn; Lin Tang; Tao Jiang; Dong-Cai Liang; Hervé Galons; Jean-Francois Dierick; Lorenzo A Pinna; Flavio Meggio; Frank Totzke; Christoph Schächtele; Andrea S Lerman; Amancio Carnero; Yongqin Wan; Nathanael Gray; Laurent Meijer
Journal:  J Biol Chem       Date:  2005-06-23       Impact factor: 5.157

7.  Identification of cytosolic aldehyde dehydrogenase 1 from non-small cell lung carcinomas as a flavopiridol-binding protein.

Authors:  J B Schnier; G Kaur; A Kaiser; S F Stinson; E A Sausville; J Gardner; K Nishi; E M Bradbury; A M Senderowicz
Journal:  FEBS Lett       Date:  1999-07-02       Impact factor: 4.124

8.  A novel genetic system to detect protein-protein interactions.

Authors:  S Fields; O Song
Journal:  Nature       Date:  1989-07-20       Impact factor: 49.962

9.  Guanidine reduces stop codon read-through caused by missense mutations in SUP35 or SUP45.

Authors:  Michael E Bradley; Sviatoslav Bagriantsev; Namitha Vishveshwara; Susan W Liebman
Journal:  Yeast       Date:  2003-05       Impact factor: 3.239

10.  Synthesis and target identification of hymenialdisine analogs.

Authors:  Yongqin Wan; Wooyoung Hur; Charles Y Cho; Yi Liu; Francisco J Adrian; Olivier Lozach; Stéphane Bach; Thomas Mayer; Doriano Fabbro; Laurent Meijer; Nathanael S Gray
Journal:  Chem Biol       Date:  2004-02
View more
  5 in total

Review 1.  Emergence and natural selection of drug-resistant prions.

Authors:  James Shorter
Journal:  Mol Biosyst       Date:  2010-04-27

2.  Prediction of antiprion activity of therapeutic agents with structure-activity models.

Authors:  Katja Venko; Špela Župerl; Marjana Novič
Journal:  Mol Divers       Date:  2013-09-20       Impact factor: 2.943

3.  A yeast-based assay identifies drugs active against human mitochondrial disorders.

Authors:  Elodie Couplan; Raeka S Aiyar; Roza Kucharczyk; Anna Kabala; Nahia Ezkurdia; Julien Gagneur; Robert P St Onge; Bénédicte Salin; Flavie Soubigou; Marie Le Cann; Lars M Steinmetz; Jean-Paul di Rago; Marc Blondel
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-29       Impact factor: 11.205

Review 4.  Translational errors: from yeast to new therapeutic targets.

Authors:  Laure Bidou; Jean-Pierre Rousset; Olivier Namy
Journal:  FEMS Yeast Res       Date:  2010-10-18       Impact factor: 2.796

5.  A synergistic small-molecule combination directly eradicates diverse prion strain structures.

Authors:  Blake E Roberts; Martin L Duennwald; Huan Wang; Chan Chung; Nicholas P Lopreiato; Elizabeth A Sweeny; M Noelle Knight; James Shorter
Journal:  Nat Chem Biol       Date:  2009-11-01       Impact factor: 15.040

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.